Mark Wysk

Mark Wysk has over 30 years of experience in the biotechnology and pharmaceutical industries. Mark currently works at Entrada Therapeutics as the Director of Quantitative Biology. Prior to that, they held positions at Sarepta Therapeutics, Seres Therapeutics, RaNA Therapeutics (now TranslateBio), OPKO Health, Inc., Pfizer, Pfizer RTC, Regeneron Pharmaceuticals, and UMass Medical School.

At Sarepta Therapeutics, Mark was a Principal Scientist from 2018 to 2021. Their responsibilities included research in the field of discovery biology.

At Seres Therapeutics, they worked as a Senior Scientist from 2016 to 2017. Mark reported to the Director of Preclinical Pharmacology and was involved in the discovery of Designed Ecobiotic Therapies for Ulcerative Colitis and Graft versus Host Disease (GVHD).

At RaNA Therapeutics (now TranslateBio), Mark served as a Senior Scientist from 2012 to 2015. Mark reported to the Senior Director of Biology and led the vivo Pharmacology Team. Mark worked on validating lncRNA targets in mice and demonstrated successful gene activation for various programs.

At OPKO Health, Inc., Mark was a Senior Scientist from 2011 to 2012. Mark was the technology development lead for evaluating pharmacokinetics of therapeutic oligonucleotides and performed target review and validation for oncology and musculoskeletal disease targets.

At Pfizer, Mark held various roles from 2007 to 2011. Mark was a Principal Scientist/Group Leader from 2009 to 2011, leading the Delivery Technology team and managing four scientists. Mark also served as a Senior Scientist from 2007 to 2009, leading the Biology team for the discovery of novel kinase inhibitors.

Before joining Pfizer, Mark worked as a Contract Scientist at Pfizer RTC from 2007 to 2007.

At Regeneron Pharmaceuticals, Mark worked as a Postdoctoral Scientist/Scientist from 2000 to 2005. Their work included co-inventing a GPCR, cell-based Two-Hybrid screen and developing subunit interaction data for secreted proteins.

Mark's career began at UMass Medical School, where they worked as a Graduate Student from 1991 to 2000. Mark focused on molecular biology and gene knockout techniques.

Overall, Mark has a diverse background in various scientific roles and has contributed to multiple research areas, including therapeutic development, pharmacology, and molecular biology.

Mark Wysk obtained a Ph.D. in Biochemistry and Molecular Biology from UMass Chan Medical School, which they attended from 1991 to 2000. Prior to that, they completed their Bachelor of Science degree in Microbiology/Medical Technology at the University of Massachusetts. However, the specific dates for their undergraduate degree are not provided.